We are live on ! Find out more
ACHN

Achillion Pharmaceuticals
ACHN

Delisted

ACHN was delisted on the 27th of January, 2020.

Back to rankings

129 hedge funds and large institutions have $467M invested in Achillion Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 43 increasing their positions, 44 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more capital invested

Capital invested by funds: $415M → $467M (+$52.2M)

8% more call options, than puts

Call options by funds: $1.85M | Put options by funds: $1.71M

6% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 18

1% less funds holding

Funds holding: 130 → 129 (-1)

2% less repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 44

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
129
Holders Change
-1
Holders Change %
-0.77%
% of All Funds
3.22%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
19
Increased
43
Reduced
44
Closed
18
Calls
$1.85M
Puts
$1.71M
Net Calls
+$135K
Net Calls Change
-$3.35M

Top Buyers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$18.2M
2
RI
RTW Investments
New York
+$6.39M
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$5.05M
4
Millennium Management
Millennium Management
New York
+$4.41M
5
SAM
Senzar Asset Management
New York
+$4.35M

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$6.49M
2
HP
HealthInvest Partners
Sweden
-$2.1M
3
SIM
Spark Investment Management
New York
-$2.07M
4
MC
Marcus Capital
Illinois
-$1.75M
5
Norges Bank
Norges Bank
Norway
-$1.53M
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$62.6M – – –
O
2
OrbiMed
New York
$60.2M – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$43.9M -$46.2K -11,488 -0.1%
BlackRock
4
BlackRock
New York
$43.7M -$1.52M -378,230 -4%
Janus Henderson Group
5
Janus Henderson Group
United Kingdom
$20.8M +$18.2M +4,526,817 New
State Street
6
State Street
Massachusetts
$18.2M -$1.38M -342,787 -8%
Goldman Sachs
7
Goldman Sachs
New York
$16.6M -$450K -111,973 -3%
BI
8
BVF Inc
California
$16M +$823K +204,677 +6%
Millennium Management
9
Millennium Management
New York
$13.8M +$4.41M +1,096,449 +57%
NI
10
Numeric Investors
Massachusetts
$13.5M -$379K -94,219 -3%
Dimensional Fund Advisors
11
Dimensional Fund Advisors
Texas
$8.58M +$5.05M +1,255,962 +205%
BBA
12
Baker Bros. Advisors
New York
$8.52M – – –
Wellington Management Group
13
Wellington Management Group
Massachusetts
$8.28M +$279K +69,420 +4%
RSCM
14
Rock Springs Capital Management
Maryland
$7.92M +$904K +225,000 +15%
Fidelity Investments
15
Fidelity Investments
Massachusetts
$7.36M +$640K +159,218 +11%
RI
16
RTW Investments
New York
$7.3M +$6.39M +1,590,454 New
Northern Trust
17
Northern Trust
Illinois
$6.55M -$232K -57,697 -4%
TA
18
Teachers Advisors
New York
$6.54M +$312K +77,524 +6%
Deutsche Bank
19
Deutsche Bank
Germany
$5.99M -$586K -145,793 -10%
BB
20
BB Biotech
Switzerland
$5.87M – – –
SAM
21
Senzar Asset Management
New York
$4.97M +$4.35M +1,082,100 New
Geode Capital Management
22
Geode Capital Management
Massachusetts
$4.92M +$282K +70,245 +7%
EAM
23
Eventide Asset Management
Massachusetts
$3.9M +$1M +250,000 +42%
JP Morgan Chase
24
JP Morgan Chase
New York
$3.9M +$1.2M +297,992 +54%
SDIC
25
South Dakota Investment Council
South Dakota
$3.87M – – –
1
2 3 4 5

ACHN Hedge Fund Activity: Q2 2017 in Review

129 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q2 2017, worth a combined $467M — up 13% from $415M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new ACHN positions and 18 closed out — a net gain of 1 holder — while 43 added to existing stakes and 44 trimmed.

The largest buyer was Janus Henderson Group, opening a new position worth an estimated $18.2M. The largest seller was Morgan Stanley, cutting an estimated $6.49M.

  • 129 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q2 2017, down from 130 in Q1 2017.
  • Funds reported $467M of Achillion Pharmaceuticals stock for Q2 2017, up 13% quarter-over-quarter.
  • 19 funds opened new Achillion Pharmaceuticals positions in Q2 2017 and 18 closed out, a net change of +1 holder.
  • The largest Achillion Pharmaceuticals buyer in Q2 2017 was Janus Henderson Group, an estimated $18.2M added.
  • The largest Achillion Pharmaceuticals seller in Q2 2017 was Morgan Stanley, an estimated $6.49M sold.

Based on aggregated 13F filings for Q2 2017.